Familial Cancer

Aims & Scope

In recent years clinical cancer genetics has become increasingly important.

Several events, in particular the developments in DNA-based technology, have contributed to this evolution.

Clinical cancer genetics has now matured to a medical discipline which is truly multidisciplinary in which clinical and molecular geneticists work together with clinical and medical oncologists as well as with psycho-social workers.

Due to the multidisciplinary nature of clinical cancer genetics most papers are currently being published in a wide variety of journals on epidemiology, oncology and genetics.

Familial Cancer provides a forum bringing these topics together focusing on the interests and needs of the clinician.

The journal mainly concentrates on clinical cancer genetics.

Most major areas in the field shall be included, such as epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counselling and the health economics of familial cancer.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2
2024	1.80

Journal Rank

Year	Value
2024	4690

Journal Citation Indicator

Year	Value
2024	329

SJR (SCImago Journal Rank)

Year	Value
2024	1.018

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	70

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

  Citation: 270

  Authors: Fred H., Eamonn R., Laura S., Lindsay A., Kristiina, Ian, Stéphane, W. Marston

• Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

  Citation: 250

  Authors: A., C., S., L., E., E. R., F., D. G. R.

• Attenuated familial adenomatous polyposis (AFAP): a review of the literature

  Citation: 231

  Authors: Anne Lyster, Marie Luise, Steffen

• Lynch Syndrome Genes

  Citation: 200

  Authors: Päivi

• Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis

  Citation: 171

  Authors: Jennifer, Kathleen M.

• Cancer risk in Lynch Syndrome

  Citation: 168

  Authors: Emma, James, D. Gareth

• Promoter Hypermethylation Frequency and BRAF Mutations Distinguish Hereditary Non-Polyposis Colon Cancer from Sporadic MSI-H Colon Cancer

  Citation: 166

  Authors: A., C.V.A., V.L.J., T., K.J., M.D., M.A., S., L.A., B.A., J., J.R.

• Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management

  Citation: 153

  Authors: Henry T., Jane F., Patrick M., Thomas

• Paragangliomas of the head and neck: diagnosis and treatment

  Citation: 148

  Authors: C. C., G. J., J.

• The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside

  Citation: 144

  Authors: C. Richard, Minoru, Dong K., John M.

---